DX1002
Tier C — Watch / tradeDX1002
Targets：CDH5, Tubulin
Indications (approved)：Hepatocellular carcinoma, 食管胃结合部肿瘤, Gastric cancer, Liver cancer, Solid tumour
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| DX1002 | 1927914-79-1 | butan-1-aminium (E)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylate |
| DX1002-001 | 951-82-6 | 2-(3,4,5-trimethoxyphenyl)acetic acid |
| DX1002-002 | 4055-69-0 | 2,3-dihydroxy-4-methoxybenzaldehyde |
| DX1002-003 | 388566-86-7 | (E)-3-(3-hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)acrylic acid |
| DX1002-004 | 109-73-9 | butan-1-amine |
Frequently asked questions
What are the approved indications of DX1002?
Approved indications include: Hepatocellular carcinoma, 食管胃结合部肿瘤, Gastric cancer, Liver cancer, Solid tumour.
When does the DX1002 patent expire?
No public expiry year is available for DX1002 yet; this page updates once verified.
How many synthesis routes are recorded for DX1002?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy DX1002 intermediates?
All intermediates in DX1002 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for DX1002 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06